PD-1 and PD-L1 Antibodies in Lung Cancer

November 20, 2013
Naiyer Rizvi, MD

Special Reports, Immunotherapy (Issue 1), Volume 1, Issue 1

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Read about predictive biomarkers ofPD-1 pathway blockade